<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775592</url>
  </required_header>
  <id_info>
    <org_study_id>NIMPE - ITM</org_study_id>
    <nct_id>NCT01775592</nct_id>
  </id_info>
  <brief_title>Plasmodium Falciparum Artemisinin Resistance Vietnam</brief_title>
  <official_title>Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Malariology, Parasitology and Entomology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Malariology, Parasitology and Entomology, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the&#xD;
      successful treatment of malaria, has been confirmed in Cambodia. There are few reports from&#xD;
      neighbouring countries about delayed parasite rates. The investigators therefore aim to&#xD;
      assess parasite clearance in malaria patients in central Vietnam when treated according to&#xD;
      national standard guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General objective To evaluate the efficacy of DHA-PPQ in patients with uncomplicated&#xD;
      falciparum malaria in a rural area of Central Vietnam, and to assess the in vitro&#xD;
      susceptibility of P.falciparum isolates to DHA and PPQ.&#xD;
&#xD;
      Specific objectives&#xD;
&#xD;
        1. To measure the parasite clearance time in falciparum malaria patients treated with&#xD;
           DHA-PPQ.&#xD;
&#xD;
        2. To determine the efficacy of DHA-PPQ at day 42 post-treatment.&#xD;
&#xD;
        3. To assess the in vitro susceptibility of P.falciparum isolates towards DHA and PPQ in&#xD;
           Quang Nam Province.&#xD;
&#xD;
        4. To compare genetic profiles of P.falciparum isolates with delayed and those with normal&#xD;
           clearance times in order to identify potential markers of resistance;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>Day 2-5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of DHA-PPQ at day 42 post-treatment in Traleng Quangnam, Vietnam</measure>
    <time_frame>Day 42</time_frame>
    <description>treatment failure or success at day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in vitro susceptibility of P.falciparum isolates towards DHA and PPQ in Quang Nam Province</measure>
    <time_frame>Day 3-10</time_frame>
    <description>MarkIII in vitro test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>genetic profiles of P.falciparum isolates with delayed and those with normal clearance times in order to identify potential markers of resistance</measure>
    <time_frame>1year</time_frame>
    <description>genotyping</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Plasmodium Falciparum</condition>
  <arm_group>
    <arm_group_label>Arterakin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - &lt; 8 years: 1.0, 1.0, 1.0, 1.0 8 - &lt; 15 years:1.5, 1.5, 1.5, 1.5&#xD;
≥ 15 years:2.0, 2.0, 2.0, 2.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arterakin (DHA-PPQ)</intervention_name>
    <arm_group_label>Arterakin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: from 6 months of age;&#xD;
&#xD;
          -  Fever (body temperature above 37.5C) or history of fever in the previous 24 hours;&#xD;
&#xD;
          -  Mono-infection with P.falciparum with parasite density between 500-100,000/µl&#xD;
&#xD;
          -  Written informed consent to participate to the trial. For patients aged less than 18&#xD;
             years, an informed consent will be obtained from a parent or a guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed malaria infection;&#xD;
&#xD;
          -  Pregnancy or lactation (urine test for β human chorionic gonadotropin to be performed&#xD;
             on any woman of child bearing age unless menstruating);&#xD;
&#xD;
          -  Concomitant acute illness necessitating specific treatment (antibiotics);&#xD;
&#xD;
          -  Underlying chronic severe illness (e.g. cardiac, renal, hepatic diseases, HIV/AIDS).&#xD;
&#xD;
          -  Severe malnutrition;&#xD;
&#xD;
          -  Danger signs:&#xD;
&#xD;
               -  not able to drink&#xD;
&#xD;
               -  incontrollable vomiting&#xD;
&#xD;
               -  recent history of convulsions (&gt;1 in 24 hours)&#xD;
&#xD;
               -  unconscious state; neurological impairment&#xD;
&#xD;
               -  unable to sit or stand&#xD;
&#xD;
          -  Signs of severe malaria:&#xD;
&#xD;
               1. Cerebral malaria (unrousable coma)&#xD;
&#xD;
               2. Severe anaemia (Htc&lt; 15%)&#xD;
&#xD;
               3. Renal failure (serum creatinine &gt; 3 mg/dL)&#xD;
&#xD;
               4. Pulmonary oedema;&#xD;
&#xD;
               5. Hypoglycemia (&lt;40mg/dL)&#xD;
&#xD;
               6. Shock (systolic BP &lt; 70 mmHg in adults, 50 in children)&#xD;
&#xD;
               7. Spontaneous bleeding&#xD;
&#xD;
               8. Repeat generalized convulsions&#xD;
&#xD;
               9. Macroscopic haemoglobinuria&#xD;
&#xD;
              10. Severe jaundice&#xD;
&#xD;
          -  Persons who have received quinine, artemisinin or artemisinin derivatives within the&#xD;
             last 7 days, 4-aminoquinolines within the last 14 days, pyrimethamine and/or&#xD;
             sulfonamides within the last 28 days, or mefloquine within the last 56 days should be&#xD;
             excluded from the in vitro testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Erhart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ITM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Centre Tra Leng</name>
      <address>
        <city>Tra Leng</city>
        <state>Quang Nam</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P.f resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

